Skip to Content

Qtern Approval History

FDA Approved: Yes (First approved February 27, 2017)
Brand name: Qtern
Generic name: dapagliflozin and saxagliptin
Dosage form: Tablets
Company: AstraZeneca
Treatment for: Diabetes, Type 2

Qtern (dapagliflozin and saxagliptin) is a sodium-glucose cotransporter 2 (SGLT2) inhibitor and dipeptidyl peptidase-4 (DPP4) inhibitor fixed-dose combination for the treatment of adult patients with type 2 diabetes.

Development History and FDA Approval Process for Qtern

DateArticle
Feb 28, 2017Approval FDA Approves Once-Daily Qtern (dapagliflozin and saxagliptin) Tablets for Adults with Type-2 Diabetes
Oct 16, 2015AstraZeneca Receives Complete Response Letter for Saxagliptin/Dapagliflozin Fixed-Dose-Combination
May 13, 2014AstraZeneca Announces Positive Results from Phase III study of Saxagliptin/Dapagliflozin Combination

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide